2004
DOI: 10.1111/j.0041-1132.2004.04173.x
|View full text |Cite
|
Sign up to set email alerts
|

Hemostatic agents

Abstract: ABBREVIATIONS: CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; DDAVP = 1-desamino-8-D -arginine vasopressin; DVT = deep vein thrombosis; EACA = epsilonaminocaproic acid; MI = myocardial infarction; rFVIIa = recombinant activated factor VIIa; TA = tranexamic acid; TF = tissue factor.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
26
0

Year Published

2006
2006
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 37 publications
(26 citation statements)
references
References 39 publications
0
26
0
Order By: Relevance
“…Some improve primary haemostasis, whereas other stimulates fibrinolysis. 12 Some are a preparation of a procoagulant substance in combination with a vehicle such as collagen matrix. Others use a matrix to provide a template for the endogenous coagulation cascade to achieve haemostasis.…”
Section: Discussionmentioning
confidence: 99%
“…Some improve primary haemostasis, whereas other stimulates fibrinolysis. 12 Some are a preparation of a procoagulant substance in combination with a vehicle such as collagen matrix. Others use a matrix to provide a template for the endogenous coagulation cascade to achieve haemostasis.…”
Section: Discussionmentioning
confidence: 99%
“…1,2 Aprotinin is a serine protease inhibitor that inhibits plasmin, trypsin, kallikrein, chymotrypsin, activated protein C, and thrombin. [9][10][11] The proteases are involved in the activation of the coagulation, fibrinolytic, and inflammation pathways. 10 Because of the effects on these pathways, the United States Food and Drug Administration has approved aprotinin as a prophylactic agent for perioperative blood loss during coronary artery bypass grafting.…”
Section: Discussionmentioning
confidence: 99%
“…EACA and tranexamic acid inhibit plasmin-mediated fibrinolysis; tranexamic acid is 10 times more potent than EACA [30]. Due to their short half-lives, lysine analogues generally require a maintenance infusion or repeated administration to achieve optimal hemostatic effect; the optimal dose is uncertain but should be reduced in patients with impaired renal function [31].…”
Section: Intraoperative Techniques To Minimize Blood Lossmentioning
confidence: 99%